Theravance Biopharma, Inc. (NASDAQ:TBPH)‘s stock had its “buy” rating restated by equities research analysts at Cantor Fitzgerald in a research note issued on Tuesday. They currently have a $55.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target points to a potential upside of 72.58% from the company’s previous close.
Other equities analysts also recently issued reports about the company. Zacks Investment Research upgraded Theravance Biopharma from a “sell” rating to a “hold” rating in a research note on Tuesday. Evercore ISI assumed coverage on Theravance Biopharma in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $45.00 price target on the stock. BidaskClub downgraded Theravance Biopharma from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. ValuEngine upgraded Theravance Biopharma from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Needham & Company LLC restated a “buy” rating on shares of Theravance Biopharma in a research note on Wednesday, August 2nd. Three analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. Theravance Biopharma currently has an average rating of “Hold” and an average price target of $41.63.
Shares of Theravance Biopharma (NASDAQ:TBPH) traded up 1.32% during mid-day trading on Tuesday, hitting $32.29. The company’s stock had a trading volume of 51,332 shares. Theravance Biopharma has a 52-week low of $23.15 and a 52-week high of $43.44. The company’s market cap is $1.74 billion. The stock’s 50 day moving average price is $29.55 and its 200 day moving average price is $35.29.
In related news, EVP Bradford J. Shafer sold 14,670 shares of Theravance Biopharma stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $30.77, for a total transaction of $451,395.90. Following the transaction, the executive vice president now directly owns 134,327 shares in the company, valued at $4,133,241.79. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Rick E. Winningham bought 10,000 shares of the stock in a transaction that occurred on Friday, August 11th. The shares were bought at an average price of $24.50 per share, for a total transaction of $245,000.00. Following the completion of the transaction, the chief executive officer now directly owns 866,377 shares of the company’s stock, valued at approximately $21,226,236.50. The disclosure for this purchase can be found here. Insiders have purchased 20,000 shares of company stock worth $494,300 over the last quarter. 6.10% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TBPH. BlackRock Inc. lifted its position in Theravance Biopharma by 117,412.4% during the first quarter. BlackRock Inc. now owns 3,512,445 shares of the biopharmaceutical company’s stock valued at $129,326,000 after purchasing an additional 3,509,456 shares in the last quarter. MARSHALL WACE ASIA Ltd purchased a new position in Theravance Biopharma during the first quarter valued at $21,862,000. Marshall Wace North America L.P. purchased a new position in Theravance Biopharma during the first quarter valued at $21,862,000. Goldman Sachs Group Inc. lifted its position in Theravance Biopharma by 341.2% during the first quarter. Goldman Sachs Group Inc. now owns 256,110 shares of the biopharmaceutical company’s stock valued at $9,430,000 after purchasing an additional 198,062 shares in the last quarter. Finally, Woodford Investment Management Ltd lifted its position in Theravance Biopharma by 1.9% during the first quarter. Woodford Investment Management Ltd now owns 10,705,108 shares of the biopharmaceutical company’s stock valued at $393,948,000 after purchasing an additional 197,500 shares in the last quarter. Institutional investors own 84.84% of the company’s stock.
About Theravance Biopharma
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.